Literature DB >> 16151426

Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time.

A Gratwohl1, R Brand, F Frassoni, V Rocha, D Niederwieser, P Reusser, H Einsele, C Cordonnier.   

Abstract

We analysed a large homogeneous group of 14,403 patients transplanted for early leukaemia from an HLA-identical sibling and reported to the EBMT in four time cohorts: 1980-1989 (24%), 1990-1994 (26%), 1995-1998 (30%) and 1999-2001 (20%). We focused on death from infection. End points were survival, death from relapse and transplant-related mortality (TRM), which was subdivided into death from graft-versus-host disease (GvHD) (1315 patients; 25% of deaths), infection (597 patients; 11% of deaths) or 'other' causes (1875 patients; 34% of deaths). Survival increased from 52% at 5 years in the first to 62% in the third cohort (P<0.05) and TRM decreased from 36 to 26% (P<0.05) due to a reduction in death from infection (P<0.001). GvHD, 'other' causes and relapse did not improve. The relative proportions of bacteria (217 patients; 36%), viruses (183 patients; 31%), fungi (166 patients; 28%) or parasites (32 patients; 5%) as cause of infectious death (cumulative incidence of death at 5 years 1.8, 1.6, 1.4 and > or = 0.3%, respectively) and median time to death from infections (3 months (range 0-158 months)) did not change. Death from infections has been reduced significantly, but it still represents an ongoing risk after HSCT and draws attention to the time beyond the initial period of neutropenia.

Entities:  

Mesh:

Year:  2005        PMID: 16151426     DOI: 10.1038/sj.bmt.1705140

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  79 in total

Review 1.  Minimal residual disease following allogeneic hematopoietic stem cell transplantation.

Authors:  Nicolaus Kröger; Koichi Miyamura; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-01       Impact factor: 5.742

2.  Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation.

Authors:  Y Tanaka; S Kurosawa; K Tajima; T Tanaka; R Ito; Y Inoue; K Okinaka; Y Inamoto; S Fuji; S-W Kim; R Tanosaki; T Yamashita; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

Review 3.  Immunotherapy for opportunistic infections: Current status and future perspectives.

Authors:  Shigeo Fuji; Jürgen Löffler; Hermann Einsele; Markus Kapp
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

4.  Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications.

Authors:  Helen L Wu; Whitney C Weber; Christine Shriver-Munsch; Tonya Swanson; Mina Northrup; Heidi Price; Kimberly Armantrout; Mitchell Robertson-LeVay; Jason S Reed; Katherine B Bateman; Eisa Mahyari; Archana Thomas; Stephanie L Junell; Theodore R Hobbs; Lauren D Martin; Rhonda MacAllister; Benjamin N Bimber; Mark K Slifka; Alfred W Legasse; Cassandra Moats; Michael K Axthelm; Jeremy Smedley; Anne D Lewis; Lois Colgin; Gabrielle Meyers; Richard T Maziarz; Benjamin J Burwitz; Jeffrey J Stanton; Jonah B Sacha
Journal:  Xenotransplantation       Date:  2020-01-13       Impact factor: 3.907

5.  Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study.

Authors:  Susan K Seo; Kun Xiao; Yao-Ting Huang; Ubonvan Jongwutiwes; Dick Chung; Molly Maloy; Sergio Giralt; Juliet N Barker; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  J Infect       Date:  2014-06-12       Impact factor: 6.072

Review 6.  Preventing stem cell transplantation-associated viral infections using T-cell therapy.

Authors:  Ifigeneia Tzannou; Ann M Leen
Journal:  Immunotherapy       Date:  2015-08-07       Impact factor: 4.196

7.  The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation.

Authors:  K A Guthrie; M Yong; D Frieze; L Corey; D N Fredricks
Journal:  Bone Marrow Transplant       Date:  2009-08-31       Impact factor: 5.483

8.  Prevention of infection transmission during stem cell transplantation.

Authors:  M Bláha; P Mericka; V Stepánová; M Splino; J Malý; L Jebavý; P Zák; M Cermanová; S Filip; M Blazek; V Rehácek
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

9.  Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype.

Authors:  Kyoko Sugimoto; Makoto Murata; Makoto Onizuka; Yoshihiro Inamoto; Seitaro Terakura; Yachiyo Kuwatsuka; Taku Oba; Koichi Miyamura; Yoshihisa Kodera; Tomoki Naoe
Journal:  Int J Hematol       Date:  2008-03-26       Impact factor: 2.490

10.  Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11).

Authors:  Walter J F M van der Velden; Thijs M P van Iersel; Nicole M A Blijlevens; J Peter Donnelly
Journal:  BMC Med       Date:  2009-09-08       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.